Avantax Planning Partners, Inc. Contrafect Corp Transaction History

Avantax Planning Partners, Inc.

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2022 Oct 14, 2022	BUY	$0.18 - $3.51 $12,600 - $245,699	70,000 Added 466.67%	85,000 $14,000
Q1 2021 May 06, 2021	BUY	$4.46 - $6.68 $66,900 - $100,200	15,000 New	15,000 $72,000

49.2K

Ticker CFRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,332,700
Market Cap $1.18M
Description
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus...

Get notified when there are updates to the investment portfolio of Avantax Planning Partners, Inc., based on Form 13F filings with the SEC.

Stay updated on Avantax Planning Partners, Inc. with notifications on news.